2022 AUA preview: Dr. Almassi on top research in bladder cancer
Nima Almassi, MD, highlights 5 studies in bladder cancer being presented at the 2022 American Urological Association Annual Meeting.
EP: 1.2022 AUA preview: Dr. Pearlman on top research in sexual dysfunction and infertility
EP: 2.2022 AUA preview: Dr. Krambeck on top research in BPH and urinary stones
EP: 3.2022 AUA preview: Dr. Almassi on top research in bladder cancer
EP: 4.2022 AUA preview: Dr. Schwen on top research in prostate cancer
In this video, Nima Almassi, MD, discusses 5 studies in bladder cancer being presented at the 2022 American Urological Association Annual Meeting. Almassi is a urologist at the Glickman Urological & Kidney Institute, Cleveland Clinic.
The following 5 abstracts are previewed:
1. LBA01-09 (Taylor et al): Interim analysis NCT04046094: IV vitamin C with chemotherapy for cisplatin ineligible bladder cancer
2. LBA01-10 (Matin et al): Interim results from a phase 1b clinical trial evaluating tolerability and activity of FGFR inhibition in localized upper tract urothelial carcinoma (UTUC)
3. PD10-01 (Galsky et al): Disease-Free Survival With Longer Follow-Up From the CheckMate 274 Trial of Adjuvant Nivolumab in Patients After Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma
4. PD26-03 (McElree et al): Sequential Intravesical Gemcitabine and Docetaxel for BCG-Naive High-Risk Non-Muscle Invasive Bladder Cancer
5. PD10-03 (Clements et al): HRQOL After Robotic-Assisted Versus Open Radical Cystectomy: Analysis of a RCT
Ra223 plus SABR does not delay progression of oligometastatic HSPC
October 3rd 2024"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
